Pharmafile Logo

Quantitative specialist joins Research Partnership, London

March 26, 2021 | New starter, Quantitative 

Global healthcare market research consultancy Research Partnership has appointed Roy Rogers as a Quantitative Director in their UK offices in London

Global healthcare market research consultancy Research Partnership has appointed Roy Rogers as a Quantitative Director in their UK offices in London. Roy is a seasoned market research professional with over 20 years’ experience in healthcare research and consulting. He joins the US Division of the company as an expert quantitative researcher, bringing with him much experience in a breadth of different research techniques.

Previously, Roy was a Partner at Hall & Partners, co-managing a team of 40 researchers. He began his career in market research at BMRB and Research International, moving into pharmaceutical market research while at Millward Brown, where he was one of the founding members of the Healthcare Practice.

Senior Director, Andrew Stokes said of his appointment, “I am delighted to welcome Roy to the company. We have a dynamic group of researchers in the London office and Roy’s quantitative experience adds another layer of expertise within the group.”

Founding Director Mary Assimakopoulos added, “We are very pleased that Roy has chosen to join Research Partnership. His specialist expertise will be a great asset to the Quantitative Centre of Excellence, which aims to stay at the forefront of best practice and innovation.”

This content was provided by Inizio

Company Details

 Latest Content from  Inizio 

Smarter science, sharper strategy: Expert insights from ASCO® 2026

As the oncology landscape continues to evolve, life sciences organizations face a growing challenge: how do you communicate increasingly complex science in a way that creates meaningful engagement?

Intelligent Commercialization™ across the pharma lifecycle

Pharma teams are under growing pressure to navigate launch complexity, identify risks earlier, and engage HCPs more effectively.

Four steps to a smarter congress strategy: A practical guidebook

This guidebook explores how Intelligent Congress helps pharma teams create more coordinated, measurable, and impactful congress strategies.

Infographic: Are data blind spots putting your launch at risk?

Commercial pharma launches depend on confident, evidence-led decisions. Yet many launch teams are still working with fragmented data spread across multiple systems, making it difficult to understand market readiness, prioritize…

Key takeaways from ASCO® 2026

Following ASCO® 2026, Inizio’s experts have shared their perspectives across three thought leadership articles, each exploring a different aspect of what this year’s congress revealed for pharmaceutical organisations. Together, they…

Webcast | Smarter science, sharper strategy: Expert perspectives from ASCO® 2026

Key insights from ASCO® 2026, including oncology trends, scientific highlights, and strategies for smarter congress engagement.

From activity to impact: 5 takeaways from MAPS Americas 2026

Across sessions, panels, and conversations on the ground in Denver, there was a noticeable shift in both mindset and momentum. Many of the themes discussed in previous years are now…

Inizio launches Intelligent Congress: Turning medical event investment into measurable impact

Inizio, the global commercialization partner to the health and life sciences industry, today announced the launch of Intelligent Congress – a connected, end-to-end solution designed to help pharma organizations maximize…

Inizio Unveils Next-Generation Hub Services at Asembia 2026, Setting a New Standard in Patient Access

Integrated capabilities combining advanced analytics, pharmacy, and specialized talent to improve access, affordability, and adherence

5 takeaways from Reuters’ Pharma USA 2026 – and what they mean for you

Pharma USA is North America’s largest cross-functional pharma event and Inizio was there to offer insights on patient engagement, accelerated product launches, and Intelligent Commercialization™. Now we’re back in the…